SCHEMBL24843293

SCHEMBL24843293

NNNc1cncc2ccccc12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRA2A P08913 1/20 0.54
ADRA2B P18089 1/20 0.54
ADRA2C P18825 1/20 0.54
ADRA1A P35348 1/20 0.54
PRKCZ Q05513 1/20 0.43
KDM4E B2RXH2 6/20 0.42
ALDH1A1 P00352 4/20 0.42
CYP3A4 P08684 3/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
TP53 P04637 2/20 0.42
GOT1 P17174 2/20 0.42
LMNA P02545 2/20 0.42
CYP1A2 P05177 2/20 0.42
CYP2D6 P10635 2/20 0.42
NPC1 O15118 1/20 0.42
MPO P05164 1/20 0.42
PKM P14618 1/20 0.42
MAOA P21397 1/20 0.42
PTGS1 P23219 1/20 0.42
THPO P40225 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2477411 0.84 ADRA2A (0.58) ADRA2AADRA2BADRA2CADRA1APRKCZ
SCHEMBL8352436 0.76 ADRA2A (0.62) ADRA2AADRA2BADRA2CADRA1APRKCZ
SCHEMBL30743841 0.76 ADRA2A (0.62) ADRA2AADRA2BADRA2CADRA1APRKCZ
SCHEMBL27844122 0.75 KDM4E (0.53) KDM4EALDH1A1CYP3A4SMN1; SMN2TP53
SCHEMBL27034898 0.74 KDM4E (0.62) ADRA2AADRA2BADRA2CADRA1APRKCZ
SCHEMBL2791578 0.73 ADRA2A (0.80) ADRA2AADRA2BADRA2CADRA1APRKCZ
SCHEMBL28594117 0.73 ALDH1A1 (0.56) ADRA2AADRA2BADRA2CADRA1AKDM4E
SCHEMBL1996604 0.72 ADRA2A (0.53) ADRA2AADRA2BADRA2CADRA1APRKCZ
SCHEMBL1996607 0.72 ADRA2A (0.53) ADRA2AADRA2BADRA2CADRA1APRKCZ
SCHEMBL13993988 0.72 ADRA2A (0.53) ADRA2AADRA2BADRA2CADRA1APRKCZ

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230002378-A1 POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS STORM THERAPEUTICS LIMITED (GB) 2023-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230002378-A1 POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS METTL3, DIMT1, TPMT ADRA2A 4389/4885ADRA2B 4446/4885ADRA2C 4323/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.